Anti-Mouse CD22 (Clone MB22-11) – Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse CD22 (Clone MB22-11) – Purified in vivo PLATINUM™ Functional Grade
Product No.: C961
Clone MB22-11 Target CD22 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names Lyb-8, Siglec-2, BL-CAM Isotype Mouse IgG2c κ Applications ELISA , FA |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Mouse Recommended Dilution Buffer Immunogen Mouse CD22 cDNA-transfected baby hamster kidney cells Product Concentration ≥ 5.0 mg/ml Endotoxin Level ≤ 0.5 EU/mg as determined by the LAL method Purity ≥95% by SDS Page ⋅ ≥98% monomer by analytical SEC Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2-8°C Wet Ice Additional Applications Reported In Literature ? ELISA, FA Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity MB22-11 activity is directed against mouse CD22 (Siglec-2). Background Siglecs (sialic acid-binding immunoglobulin superfamily lectins) are a family of single pass, transmembrane cell surface proteins characterized by shared structural motifs and an ability to recognize sialic acids1, 2. CD22 (Siglec-2), a 140 kDa member of the Siglec family expressed by B cells3, 4, contains six C2-set domains, one V-set domain, and in its intracellular cytoplasmic tail has three immunoreceptor tyrosine-based inhibition motifs (ITIM) and one ITIM-like domain5. While murine Siglecs are not necessarily homologous to human Siglecs, CD22 is evolutionarily conserved and does have a direct human ortholog5. CD22 acts as an inhibitory B cell co-receptor that negatively regulates B cell activation, B reg cell expansion, and B cell receptor (BCR) signaling4. Upon ligation of BCR, ITIMs are phosphorylated, leading to recruitment and activation of SH2-containing phosphatases that then dephosphorylate signaling molecules activated by BCR ligation4. Additionally, CD22 regulates B cell response to inflammation and is a master regulator of microglial phagocytosis in the aging brain5. Evidence in mouse models suggests CD22 contributes to the pathogenesis of autoimmune diseases3. Loss of CD22 leads to hyperactivation of B cells5. CD22 mouse knockouts are defective in B cell development but do not develop lupus-like disease4. To generate MB22-11, CD22 knockout mice were immunized with mouse CD22 cDNA-transfected baby hamster kidney cells6. Spleen cells were fused with NS-1 myeloma cells, and hybridomas producing antibody specifically reactive with CD22-transfected mouse L cells were selected and purified. MB22-11 was isotyped as IgG2c due to its C57BL/6 origin; however, both IgG2a and IgG2c specific reagents have significant reactivity against MB22-11. In vitro, MB22-11 inhibits CD22-mediated adhesion by 90% and completely blocks CD22-Fc binding to T and B cells6. In vivo, MB22-11 significantly reduces peripheral blood, lymph node, and marginal zone B cell numbers6, 7. Additionally, in mice injected with MB22-11, blood, spleen, and lymph node B cell turnover is higher relative to injection with non-blocking monoclonal antibodies, and B cell surface expression of CD22 is reduced to nearly undetectable levels6. Antigen Distribution CD22 is expressed by most mature B cell lineages. Ligand/Receptor SHP-1, Syk, Lck, and Lyn NCBI Gene Bank ID UniProt.org Research Area Cell Adhesion . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. The MB22-11 clone is a mouse anti-mouse CD22 monoclonal antibody that serves as a valuable research tool for B cell depletion studies in mouse models. This antibody specifically targets CD22, a member of the SIGLEC family of lectins expressed on mature B cells, and has distinct mechanisms and applications in experimental research. Mechanism of ActionMB22-11 functions by blocking CD22-ligand interactions rather than through traditional antibody-dependent cellular cytotoxicity (ADCC) mechanisms. The antibody interferes with CD22 ligand binding, which is an important survival factor for peripheral B cells. In vitro studies demonstrate that MB22-11 inhibits CD22-mediated adhesion by 90% and completely blocks CD22-Fc binding to T and B cells. B Cell Depletion PropertiesThe antibody exhibits selective B cell depletion patterns that differ from other B cell-targeting antibodies like anti-CD20. MB22-11 specifically depletes mature recirculating bone marrow B cells (approximately 49-58%), blood B cells (75-84%), and marginal zone B cells (77-82%) in both C57BL/6 and NZB/W F1 mice. Notably, it only depletes about 20% of mature CD22+ follicular B cells, making it particularly useful for studying specific B cell subsets. The depletion is rapid and selective, targeting CD1d^high^CD21^high^B220+ marginal zone B cells and IgM^bright^CD23- marginal zone B cells. Importantly, marginal zone B cell numbers begin to replenish within 3 weeks following a single 250 ?g injection, allowing for temporal studies of B cell recovery. Effects on B Cell Turnover and FunctionMB22-11 treatment significantly increases B cell turnover rates in peripheral tissues. Seven days following treatment, blood, spleen, and lymph node B cell turnover increases by as much as 4-fold compared to control antibody-treated mice. This enhanced turnover is accompanied by increased frequencies of BrdU+ (cycling) B220+ cells and decreased numbers of BrdU- (non-cycling) B cells in spleen and lymph nodes. The antibody also reduces CD22 surface expression to nearly undetectable levels on B cells following in vivo administration. This down-modulation of CD22 expression occurs alongside the functional blocking of CD22-ligand interactions. Research ApplicationsMB22-11 has been extensively used in autoimmune disease models to investigate B cell functions. Studies have employed this antibody in mouse models of systemic lupus erythematosus, tight skin fibrosis, experimental autoimmune encephalomyelitis (EAE), type 1 diabetes, collagen and proteoglycan-induced arthritis, and thyroiditis. In lupus studies using NZB/W F1 mice, researchers have found that B cells can exert both pathogenic and protective functions at different time points during disease progression. The antibody is also valuable for studying B cell homeostasis and has been used in combination with other treatments, such as BLyS/BAFF-blocking antibodies, to understand complementary pathways in B cell survival. Dosing and AdministrationTypical experimental doses range from 100 ?g to 250 ?g per mouse, administered as single injections. The antibody is available in purified, in vivo GOLD functional grade formulations specifically designed for animal studies. The effects are measurable within days of administration and can be monitored over several weeks to assess both depletion and recovery phases. Looking at the information about the Anti-Mouse CD22 (Clone MB22-11) sterile packaged product, the correct storage temperature is 2-8°C for short-term storage. Storage GuidelinesShort-term storage: The functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. Long-term storage: For longer term storage, the product should be aseptically aliquoted in working portions, though the specific temperature for long-term storage is not detailed in the available information. This temperature range of 2-8°C (equivalent to 36-46°F) is a standard refrigerated storage condition commonly used for biological products to maintain their stability and functionality while preventing degradation that could occur at higher temperatures or damage from freezing. Commonly, MB22-11 (an anti-mouse CD22 monoclonal antibody) is used in conjunction with other antibodies or proteins targeting B cell surface markers or involved in B cell depletion, immunophenotyping, or mechanistic studies in immunology. The most frequently co-used antibody is MB20-11 (anti-mouse CD20), another depleting antibody that targets a separate population of B cells. Key antibodies and proteins used alongside MB22-11 in the literature include:
Other markers and antibodies (often for immunophenotyping or disease models) that may be found alongside MB22-11 in panels include:
In summary, MB22-11 is most frequently used with anti-CD20 (MB20-11), isotype controls, detection antibodies, and sometimes markers of B cell subpopulations and signaling pathway proteins in the context of murine immunological and autoimmune disease research. Key Findings from Clone MB22-11 in Scientific LiteratureClone MB22-11 is a monoclonal antibody (mAb) targeting CD22, a molecule expressed on B cells, and is used primarily as a research tool for understanding B cell biology and modulation of antibody signaling. Mechanism of Action
Phenotypic Changes in B Cells
Biological Implications
Summary Table
ConclusionClone MB22-11 is a potent, ligand-blocking CD22 antibody that profoundly affects B cell survival and turnover by disrupting critical CD22-ligand interactions, leading to depletion of mature B cell subsets and altered surface marker profiles in surviving B cells. It is widely used to study B cell survival mechanisms and CD22 signaling in vivo. References & Citations1. Bochner BS. Clin Exp Allergy. 39(3):317-324. 2009. 2. Kiwamoto T, Kawasaki N, Paulson JC, et al. Pharmacol Ther. 135(3):327-336. 2012. 3. Dörner T, Shock A, Smith KG. Int Rev Immunol. 31(5):363-378. 2012. 4. Tsubata T. Immunol Med. 42(3):108-116. 2019. 5. Siddiqui SS, Matar R, Merheb M, et al. Cells. 8(10):1125. 2019. 6. Haas KM, Sen S, Sanford IG, et al. J Immunol. 177(5):3063-3073. 2006. 7. Haas KM, Watanabe R, Matsushita T, et al. J Immunol. 184(9):4789-4800. 2010. Technical Protocols FA Certificate of Analysis |
Formats Available
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
